Biomerica, a Delaware-incorporated microcap diagnostic test developer listed on Nasdaq, took an unusual step in late May when it agreed to sell back to buyers affiliated with Chief Executive Officer Zackary Irani the roughly six percent stake the company held in Diagnosis S.A., a Białystok, Poland-based medical-products distributor, for $500,000 paid through a secured promissory note that bears 8% interest and matures 12 months out, with the principal and most of the interest forgiven upon successful share transfer. The transaction, disclosed in a Form 8-K filed on June 4, 2026 with the event date of May 29, 2026, makes the chief executive a direct counterparty to the company on a structured instrument that the disclosure itself flags as a related-party transaction. The strategic implication is that the company is monetizing a non-core European asset to buy itself operating runway, but it is doing so on terms that depend on Polish regulatory approvals, expected to be obtained within thirty days, and that convert the headline $500,000 of monetized value into an effective structured loan rather than a hard cash inflow.
The principal question for the next twelve months is whether the Polish regulatory approval completes on the contemplated timeline, and whether the inFoods IBS (irritable bowel syndrome) and hp+detect H. pylori platforms can produce a sustained revenue inflection before the company's $1.34 million cash balance at February 28, 2026 is consumed by the underlying cash-burn profile. The disclosure cadence that the next several quarters resolve is, in order of importance, the completion of the Polish regulatory approval for the Irani note and the consequent forgiveness of principal and most interest, the commercial adoption cadence of the hp+detect H. pylori test and any national-distribution partnership announcement, the additional clinical evidence and payer-coverage decisions for the inFoods IBS platform, the cash position at the end of fiscal 2026 and the company's plan for the May 2027 maturity of the Irani note, and any further related-party or financing transactions.